A preliminary study of the safety, immunogenicity and clinical efficacy of TroVax® given in conjunction with interleukin 2 (IL-2) in the treatment of stage IV renal cell cancer
| ISRCTN | ISRCTN83977250 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN83977250 |
| ClinicalTrials.gov number | NCT00083941 |
| Secondary identifying numbers | TV2Renal |
- Submission date
- 16/10/2008
- Registration date
- 10/11/2008
- Last edited
- 01/02/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Howard Kaufman
Scientific
Scientific
New York-Presbyterian Hospital/Columbia
Milstein Hospital Bldg Room 7SK
177 Fort Washington Avenue
New York
10032
United States of America
Study information
| Study design | Interventional phase II open-label single-arm trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Other |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. |
| Study objectives | To determine the safety of TroVax® administered to renal cancer patients alongside interleukin 2 (IL-2). |
| Ethics approval(s) | This study was approved by the Columbia University Institutional Review Board on 08/18/2004 (ref: A0805). |
| Health condition(s) or problem(s) studied | Renal cancer |
| Intervention | Patients complying with the entry criteria will be invited to enter the study. After giving fully informed consent, patients will be subjected to a medical history and physical examination to document general fitness to proceed with the trial. Previous exposure to small pox vaccine will be noted. The diagnosis should be confirmed histologically from the patient's records. If possible, a retained sample will be obtained to stain for 5T4. If a fresh sample is taken, it may be cryopreserved and also examined for 5T4. At that time, metastases will be documented using relevant CT scans (chest, abdomen, pelvic). An MRI scan of the brain will be obtained. A cardiac stress test and pulmonary function tests will be obtained in appropriate patients. Blood will also be drawn for haematology and clinical chemistry, full blood count with differential white cell and platelet counts, urea and electrolytes, liver function tests (total bilirubin, AST, ALT, GGT, alkaline phosphatase), serum proteins, calcium, phosphate, glucose and creatinine), pituitary hormone screen (ACTH, TSH, LH, FSH), antinuclear and anti-skeletal muscle antibodies and immunological testing (antibodies to 5T4 and vector, cellular responses to 5T4; 100 ml). In potentially fertile women, a pregnancy test will be obtained. A urine sample will be obtained for urinalysis for protein and blood. This screen should not occur more than two weeks before the immunisation schedule begins. At week 0, the patients will be immunised with a single intramuscular injection of 1 ml of TroVax® 10x. This dose will be given without IL-2. Then, every three to four weeks for four injections, TroVax® will be given in the morning. These doses may be given in conjunction with IL-2. Immediately before each injection, blood will be drawn for immunological testing (100 ml). Before the injection, blood will also be drawn for clinical pathology (full blood count and clinical chemistry). A urine sample will be obtained for urinalysis for protein and blood. IL-2 will be given intravenously (IV) in a dose of 600,000 IU/kg every eight hours for up to 15 injections in each cycle. The first dose will be given in the afternoon of the same day as the second TroVax® injection. These cycles of TroVax® and IL-2 will be repeated every 3-4 weeks depending upon patient tolerance and clinical response. Cycles of IL-2 will always commence in the afternoon after TroVax® has been given in the morning. If IL-2 is not tolerated, it may be suspended but treatment with TroVax® will be continued so long as it is well tolerated. TroVax® may be given for up to three months (i.e. injection 5) to patients with progressive disease so long as no other anticancer treatment (i.e. chemotherapy, interferon alpha or radiotherapy) is considered indicated for them. CT scans (chest abdomen, pelvis) will be obtained to restage the disease at weeks 9-10 and 15-16 (i.e. after two and four doses of IL-2 and/or 3 and 5 doses of TroVax®). A blood sample for immunological testing (100 ml) will be obtained three and eight weeks after the fifth TroVax® injection (4 and 5 months). Following the CT scan at 15-16 weeks patients will be followed at three monthly intervals, commencing at six months. Patients whose disease is progressing at this point may not be treated further with TroVax® but may be kept on study and observed at three monthly intervals. Patients whose disease has stabilised or responded will be offered three further injections of TroVax® at months 6, 9 and 12. Patients whose disease progresses or who experience serious or severe adverse events related to TroVax® will stop treatment with TroVax® but may be kept on study and reviewed at three monthly intervals. If the patient requires further treatment with established anticancer agents, these will be recorded in the CRF. At each visit, from week 12 to month 12, regardless of disease status, blood will be obtained (prior to the injection of TroVax®, if indicated) for clinical pathology, pituitary hormone screen, autoantibodies and immunological testing (100 ml). A urine sample will be obtained for urinalysis for protein and blood. The disease will be restaged using CT scans (chest abdomen, pelvis). When TroVax® is being administered, patients will return 3 weeks after each TroVax® injection for immunological testing (100 ml). After month 12, patients will return at three monthly intervals for a further 12 months. At each visit, the disease will be restaged using CT scans (chest abdomen, pelvis) in accordance with current institutional guidelines. Blood (100 ml) will be obtained for immunological testing, autoantibodies and pituitary function tests. A urine sample will be obtained for urinalysis for protein and blood. Patients, who at the end of this period, have stable or responding disease may be followed at three monthly intervals until disease progression occurs. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase I/II |
| Drug / device / biological / vaccine name(s) | TroVax® |
| Primary outcome measure | Safety: 1. To assess the safety and tolerability of TroVax® injections when given as a therapeutic vaccine to patients with metastatic renal cell cancer. Safety was assessed for a maximum of 24 months or however long the patients remained on study. 2. To assess the immune responses induced by treatment with TroVax®. Immunology was assessed throughout the protocol for a maximum of 24 months or until the patient came off the study. |
| Secondary outcome measures | Efficacy: The following were assessed using computerised tomography (CT) scans at baseline, Week 10, 16 and then every 3 months up to 24 months or as long as the patient remained on study: 1. Tumour response rates 2. Time to disease progression 3. Two year survival |
| Overall study start date | 01/01/2004 |
| Completion date | 11/07/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 25 |
| Key inclusion criteria | 1. Both males and females, aged 18 years or more 2. Metastatic renal clear cell adenocarcinoma, histologically proven by biopsy of the primary tumour and/or a metastasis. If a fresh specimen is obtained for diagnostic purposes, it may be frozen and stained for 5T4. Prior nephrectomy is not required. 3. Requiring treatment with IL-2 and able to tolerate a high dose schedule per institutional standards 4. Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1 5. Expected survival longer than three months 6. No clinically active autoimmune disease 7. Total white cell count d 3 x 10^9/l 8. Platelet count d 90,000/mm^3 9. Serum creatinine 1.6 mg/dl or less 10. Total bilirubin 1.6 mg/dl or less 11. Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) T three times the upper limit of normal or 5 times upper limit of normal if liver metastases are present 12. Able to give written informed consent and to comply with the protocol 13. Women must be either post menopausal, rendered surgically sterile or practising a reliable form of contraception (hormonal, intrauterine device or barrier). Men must practise an effective form of birth control, such as barrier protection. 14. Normal cardiac stress test if the patients are older than 50 years of age or have symptoms of cardiac disease 15. Normal pulmonary function tests if the patient is a smoker or is known to have primary lung disease |
| Key exclusion criteria | 1. Pregnancy, lactation or lack of effective contraception in fertile men and women of childbearing potential 2. Intercurrent serious infections within the 28 days prior to entry to the trial 3. Known to be HIV positive because HIV infection can lead to serious adverse events with vaccination and/or high-dose IL-2 4. Life threatening illness unrelated to cancer 5. Cerebral metastases 6. History of allergic response to previous vaccinia vaccinations 7. Participation in any other clinical trial within the previous 30 days 8. Previous malignancies within the last two years other than successfully treated squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone biopsy 9. Previous history of major psychiatric disorder requiring hospitalisation or any current psychiatric disorder that would impede the patient's ability to provide informed consent or to comply with the protocol 10. Corticosteroids unless used as an antiemetic 11. Family contact with active eczema, exfoliative skin disorder, pregnancy or other cause of immunocompromise |
| Date of first enrolment | 01/01/2004 |
| Date of final enrolment | 11/07/2008 |
Locations
Countries of recruitment
- United States of America
Study participating centre
New York-Presbyterian Hospital/Columbia
New York
10032
United States of America
10032
United States of America
Sponsor information
Oxford BioMedica (UK)
Industry
Industry
The Medawar Centre
The Oxford Science Park
Oxford
OX4 4GA
United Kingdom
| Website | http://www.oxfordbiomedica.co.uk |
|---|---|
"ROR" |
https://ror.org/03dp0vf82 |
Funders
Funder type
Industry
Oxford BioMedica (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 07/01/2009 | 01/02/2019 | Yes | No |
Editorial Notes
01/02/2019: Publication reference added
